QIAGEN has unveiled a new suite of target enrichment panels designed to support long-read sequencing technologies, aiming to improve genomic analysis in complex regions of the genome. The new QIAseq xHYB Long Read Panels are optimized for use with native long-read platforms, including those from PacBio, and are intended to address known limitations of short-read sequencing approaches.
The panels are geared toward research areas such as HLA typing, repeat expansion disorders, and structural variant detection, domains where high-fidelity phasing and resolution remain critical yet challenging with conventional sequencing methods. Built on hybrid-capture chemistry, the panels offer both fixed and customizable formats and are compatible with high-molecular-weight DNA extraction protocols. According to the company, the offering integrates with its bioinformatics platform for downstream analysis and interpretation.
The release comes amid growing interest in long-read sequencing within translational and clinical research contexts. Native long-read technologies, unlike synthetic alternatives, allow for the direct analysis of longer DNA fragments, enabling more accurate detection of structural variants and complex genomic features such as repeats and haplotypes.
In a statement, Nitin Sood, Head of Product Portfolio and Innovation at QIAGEN, framed the launch as part of a broader investment in genomic tools tailored for both research and potential clinical use. The launch also coincides with increased uptake of PacBio’s benchtop sequencer, Vega, which employs high-fidelity (HiFi) long-read sequencing. David Miller, PacBio’s Vice President of Global Marketing, noted that the expanded toolkit could support growing demand for high-resolution targeted sequencing in clinical and translational settings.